Special Issue

From Population to Precision: Nutritional Approaches in Metabolic Dysfunction-Associated Steatotic Liver Disease

Message from the Guest Editors

The liver is central to metabolic regulation, coordinating nutrient processing and energy balance to maintain whole-body homeostasis. MASLD, formerly known as NAFLD, is the most common chronic liver disease globally, largely driven by poor diet, sedentary lifestyle, obesity, and type 2 diabetes. Nutrition plays a key role in both the development and management of MASLD by influencing liver fat, insulin sensitivity, inflammation, and fibrosis. Dietary interventions that promote weight loss and improve metabolic function can slow disease progression. Personalized nutrition strategies, tailored to individual genetic and metabolic profiles, hold strong therapeutic promise. This Special Issue highlights innovative research on nutrition's role in MASLD prevention and management, from clinical trials to mechanistic studies. Topics include nutrient-gene interactions, Mendelian randomization for causal inference, and omics-driven personalized strategies. It covers both established and emerging perspectives on nutritional therapies and dietary guidelines. Population differences, genetic backgrounds, and commercial diets are also explored. You may choose our Joint Special Issue in Nutrients.

Guest Editors

Dr. Marijana Vujkovic

- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA 19104, USA
- 2. Translational Medicine and Human Genetics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA
- Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

Dr. Kate Townsend Creasy

- 1. Biobehavioral Health Sciences, University of Pennsylvania School of Nursing, Philadelphia, PA 19104, USA
- Translational Medicine and Human Genetics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA



Livers

an Open Access Journal by MDPI

Impact Factor 2.4 CiteScore 3.2



mdpi.com/si/244979

Livers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
livers@mdpl.com

mdpi.com/journal/ livers





Livers

an Open Access Journal by MDPI

Impact Factor 2.4 CiteScore 3.2



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Hartmut W. Jaeschke

Department of Pharmacology, Toxicology & Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, USA

Author Benefits

High Visibility:

indexed within ESCI (Web of Science), Scopus, EBSCO, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 27.8 days after submission; acceptance to publication is undertaken in 6.7 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.

